On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Save 20% on Press Releases and More with NNW Prime! Click to View Details
TuesdayDec 13, 2016 3:01 pm

NetworkNewsBreaks – Revance Therapeutics, Inc. (RVNC) Reports Positive Preliminary from Phase 2 Cervical Dystonia Trial

Shares of Revance Therapeutics (NASDAQ: RVNC) are ticking higher after the biotech company reported positive interim results from its U.S. phase 2 open-label, dose-escalating clinical study of DaxibotulinumtoxinA Injectable (RT002) to treat moderate-to-severe isolated cervical dystonia in adults, a movement disorder of the neck. Final results are expected in the first half of 2017. “ … I am particularly encouraged that in this trial RT002 exhibited a safety profile at least as good as currently marketed neurotoxins. Furthermore, with a sustained median duration of at least 24 weeks, there is a possibility that patients will require injections only two times…

Continue Reading

TuesdayDec 13, 2016 2:51 pm

NetworkNewsBreaks – Organovo (ONVO) Presenting 3D Bioprinted Human Liver Tissue Data at TERMIS-Americas Meeting

Organovo Holdings, Inc. (NASDAQ: ONVO) is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models at the ongoing TERMIS-Americas Meeting in San Diego. Organovo intends to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its therapeutic liver tissue in three to five years. “Our preclinical data show rapid vascularization and tissue engraftment, and evidence of function and durability of our 3D bioprinted human liver tissue over several weeks.  Most importantly, we see evidence of stable production of key human liver…

Continue Reading

TuesdayDec 13, 2016 2:45 pm

NetworkNewsBreaks – Soligenix, Inc. (SNGX) Prices $5,277,000 Public Offering, Debuts on Nasdaq

Soligenix (NASDAQ: SNGX, SNGXW) shares are 34% lower on its first day of uplisting to the Nasdaq Capital Market. The late-stage biopharmaceutical company this morning priced an underwritten public offering of 1,670,000 shares of its common stock and warrants to purchase up to an aggregate of 2,087,500 shares of its common stock at a combined offering price of $3.16 – for gross proceeds of approximately $5,277,200. The warrants will have an initial per share exercise price of $3.95, subject to customary adjustment in connection with stock splits, stock dividends, reclassifications, combinations and other similar events; are exercisable immediately; and will…

Continue Reading

TuesdayDec 13, 2016 2:08 pm

NetworkNewsBreaks – Neovasc, Inc. (NVCN), Boston Scientific Corp. (BSX) Close $75M Acquisition Deal; Shares of Both Higher

Neovasc (NASDAQ: NVCN) and Boston Scientific (NYSE: BSX) this morning reported the close of their previously announced $75 million agreement in which Boston Scientific has acquired Neovasc's advanced biologic tissue capabilities and certain manufacturing assets, as well as 11,817,000 common shares at a price of $0.60 each ($7.0 million) for a 15% equity interest in Neovasc. Per the agreement, Neovasc has been granted a license to the purchased assets and access to the facilities in order to continue its assembly activities for its remaining tissue and valve customers. Neovasc said it intends to use the proceeds of these transactions toward…

Continue Reading

MondayDec 12, 2016 1:39 pm

NetworkNewsBreaks – Nano Dimension (NNDM): Capabilities of “Holy Grail of 3D Printers” on Display at CES 2017

Nano Dimension (NASDAQ, TASE: NNDM) this morning said it will showcase its DragonFly 2020™  3D printer during CES 2017, an annual global consumer electronics and consumer technology tradeshow taking place January 5-8, 2017,  in Las Vegas, Nevada. Visitors to Nano Dimension’s booth will see a wide range of fully functioning circuits printed by the 'Holy Grail of 3D Printers' – a label given to DragonFly 2020 by CNET at last year’s CES tradeshow. "Nano Dimension prints 3D-print circuitry in non-planar free-form circuits, which is an enormous area of untapped potential. There's no doubt that 3D printing will shape the design…

Continue Reading

MondayDec 12, 2016 1:36 pm

NetworkNewsBreaks – Jaguar Animal Health (JAGX) Inks Distribution Deal with Henry Shein, Inc.; Shares Spike

Shares of Jaguar Animal Health, Inc. (NASDAQ: JAGX) are up 23%, triggered by news of the company’s agreement with Henry Schein, Inc. for one year of exclusive distribution of Jaguar’s Neonorm™ Foal product to the U.S. equine market. “We are very excited to have the support of one the world’s leading companion animal health distribution companies in our effort to drive sales of Neonorm™ Foal throughout the U.S. equine market,” Lisa Conte, Jaguar’s president and CEO, stated in the news release. “We look forward to leveraging the great exposure that Neonorm™ Foal received at last week’s AAEP conference and collaborating closely…

Continue Reading

MondayDec 12, 2016 1:33 pm

NetworkNewsBreaks – Neuralstem, Inc. (CUR) Shares Higher; finalizes $20M Strategic Investment from Tianjin Pharmaceutical Group

Neuralstem (NASDAQ: CUR) is trading 9% higher after reporting the close of a $20 million investment from Tianjin Pharmaceutical Group International Holdings Co., LTD in an arrangement Neuralstem says will “complement and support” R&D initiatives. Tianjin received 28.5 million shares of common stock and 1 million shares of Series A convertible preferred stock that cannot be converted if the shares received and the common shares would result in Tianjin having voting power in excess of 19.99% of the company. Tianjin is also authorized to appoint one member to the company’s board of directors. To view the full press release, visit:…

Continue Reading

FridayDec 09, 2016 2:13 pm

NetworkNewsBreaks – A. M. Castle & Co. (CASL) Secures $112M in new Secured Term Credit Facilities

A. M. Castle & Co. (OTCQB: CASL) closed a definitive agreement for new credit facilities of $112 million, which the company intends to use to repay outstanding borrowings and support the continuance of letters of credit, totaling $53.2 million under a former revolving loan and security agreement. “These new credit facilities will enhance Castle’s liquidity and better position the Company to advance its ongoing efforts to capitalize on market opportunities. We are excited to have the support of the financial institutions funding the Credit Facilities,” Castle president and CEO Steve Scheinkman stated in the news release. To view the full…

Continue Reading

FridayDec 09, 2016 2:00 pm

NetworkNewsBreaks – Long Island Iced Tea Corp. (LTEA) Inks First Acquisition Deal; Shares Tick Higher

Long Island Iced Tea Corp. (NASDAQ: LTEA) this morning said it will acquire the ALO Juice® beverage brand and trademark rights from The Wilnah International, LLC for a purchase price of 5,000 shares of the company's common stock. The company has been distributing ALO Juice® since February 2016, with nearly $1 million worth sold to date. The closing of the transaction is anticipated for the first quarter of 2017, subject to customary conditions. "ALO Juice® is a quality brand. We are excited that it will mark the first brand acquisition in our five-year history," Long Island Iced Tea CEO Philip…

Continue Reading

ThursdayDec 08, 2016 1:59 pm

NetworkNewsBreaks – Anavex Life Sciences (AVXL) Releases Positive Data for ANAVEX 2-73 in Alzheimer’s Study; Trading Higher

Shares of Anavex Life Sciences (NASDAQ: AVXL) are higher after the company said its ANAVEX 2-73 candidate met primary and secondary endpoints in a phase 2a study of patients with mild-to-moderate Alzheimer’s disease (AD). ANAVEX 2-73 was well tolerated and there were no clinically significant treatment-related adverse events and no serious adverse events. Despite non-optimized dosing of ANAVEX 2-73 throughout the 12-month study, continued significant improvements from baseline of cognitive, functional and behavioral scores in a group of patients were observed, respectively. "We believe this data gives us a solid foundation from which to continue the next phase of rationally…

Continue Reading

Contact us: 212.418.1217